Table 1 Serogroup 19 isolates from children <5 years of age, in NSW.

From: Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia

Serogroup 19/total (%)

Year

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

Total IPD isolates from children <5 yrs (all serotypes)

245a

141

71

81

99a,b

73

95

73

66

60

80b

58

63

Total serogroup 19

41a (17)

33 (23)

21 (30)

35 (43)

60a,b (61)

42 (58)

40 (42)

40 (55)

22 (33)

13 (22)

23a,b (29)

19 (33)

10 (16)

Serotype 19F

32c (13)

19 (14)

8 (11)

4 (5)

43,4 (4)

5 (6)

1 (1)

3 (4)

2 (3)

74 (9)

10 (17)

6 (10)

Serotype 19A

93 (4)

14 (10)

13 (18)

31 (38)

56c (57)

37 (51)

39 (41)

37 (55)

20 (30)

13 (22)

16d (20)

9 (16)

4 (6)

Vaccine Failuree - Serotype 19F

N/A

N/A

N/A

3 (3)

3 (4)

1 (1)

2 (3)

3f,g (4)

7 (12)

4 (6)

Vaccine Failuree - Serotype 19A

N/A

N/A

N/A

5 (8)

9g,i (11)

6 (10)

4 (6)

  1. Notes:
  2. aIncrease in number and proportion of serogroup 19 between 2004 and 2008; p = 0.0001.
  3. bDecrease in number and proportion of serogroup 19 between 2008 and 2014: p < 0.01.
  4. cShift of predominant serotype from 19F to 19A after the introduction of PCV-7: p = 0.0001.
  5. dIncrease in number and proportion of serotype 19F after introduction of PCV-13 p < 0.01.
  6. eVaccine failure defined as IPD in children who had received the recommended 3 doses of PCV-7 and/or PCV-13.
  7. fTwo vaccine failures were in children with co-morbidities associated with increased risk of IPD.
  8. gOne vaccine failure case was reported in a child with co-morbidities associated with an increased risk of IPD.
  9. hTwo serotype 19F vaccine failure cases where fully vaccinated with PCV-7, one case was fully vaccinated with PCV-13.
  10. iAll 9 cases of 19A vaccine failure where fully vaccinated with PCV-13.